Do analysts prefer CBUS or BLGO?

Cibus currently has a consensus target price of $9.00, indicating a potential upside of 429.41%. Given Cibus' stronger consensus rating and higher possible upside, equities research analysts plainly believe Cibus is more favorable than BioLargo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cibus 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 BioLargo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, CBUS or BLGO?

BioLargo has higher revenue and earnings than Cibus. BioLargo is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cibus $3.64M 35.65 -$127.08M -$1.97 N/A BioLargo $12.23M 3.01 -$3.50M -$0.04 N/A

Is CBUS or BLGO more profitable?

BioLargo has a net margin of -11.45% compared to Cibus' net margin of -2,366.33%. BioLargo's return on equity of -39.90% beat Cibus' return on equity. Company Net Margins Return on Equity Return on Assets Cibus -2,366.33% -200.87% -28.28% BioLargo -11.45% -39.90% -22.06%

Does the media refer more to CBUS or BLGO?

In the previous week, Cibus had 4 more articles in the media than BioLargo. MarketBeat recorded 6 mentions for Cibus and 2 mentions for BioLargo. Cibus' average media sentiment score of 0.77 beat BioLargo's score of 0.46 indicating that Cibus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cibus 0 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioLargo 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate AMTX or BLGO?

Aemetis presently has a consensus price target of $11.88, suggesting a potential upside of 604.75%. Given Aemetis' stronger consensus rating and higher possible upside, research analysts plainly believe Aemetis is more favorable than BioLargo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aemetis 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 BioLargo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is AMTX or BLGO more profitable?

BioLargo has a net margin of -11.45% compared to Aemetis' net margin of -35.43%. Aemetis' return on equity of 0.00% beat BioLargo's return on equity. Company Net Margins Return on Equity Return on Assets Aemetis -35.43% N/A -33.44% BioLargo -11.45% -39.90% -22.06%

Does the media refer more to AMTX or BLGO?

In the previous week, Aemetis had 1 more articles in the media than BioLargo. MarketBeat recorded 3 mentions for Aemetis and 2 mentions for BioLargo. Aemetis' average media sentiment score of 0.83 beat BioLargo's score of 0.46 indicating that Aemetis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aemetis 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioLargo 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ARQ or BLGO?

ARQ presently has a consensus price target of $5.00, suggesting a potential upside of 146.31%. Given ARQ's stronger consensus rating and higher probable upside, equities analysts plainly believe ARQ is more favorable than BioLargo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ARQ 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 BioLargo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, ARQ or BLGO?

BioLargo has lower revenue, but higher earnings than ARQ. BioLargo is trading at a lower price-to-earnings ratio than ARQ, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ARQ $122.14M 0.71 -$52.61M -$1.29 N/A BioLargo $12.23M 3.01 -$3.50M -$0.04 N/A

Is ARQ or BLGO more profitable?

BioLargo has a net margin of -11.45% compared to ARQ's net margin of -43.93%. ARQ's return on equity of -2.67% beat BioLargo's return on equity. Company Net Margins Return on Equity Return on Assets ARQ -43.93% -2.67% -2.00% BioLargo -11.45% -39.90% -22.06%

Does the media prefer ARQ or BLGO?

In the previous week, ARQ had 1 more articles in the media than BioLargo. MarketBeat recorded 3 mentions for ARQ and 2 mentions for BioLargo. ARQ's average media sentiment score of 0.63 beat BioLargo's score of 0.46 indicating that ARQ is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARQ 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioLargo 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer FSI or BLGO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Flexible Solutions International 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 3.00 BioLargo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media refer more to FSI or BLGO?

In the previous week, Flexible Solutions International had 2 more articles in the media than BioLargo. MarketBeat recorded 4 mentions for Flexible Solutions International and 2 mentions for BioLargo. BioLargo's average media sentiment score of 0.46 beat Flexible Solutions International's score of 0.40 indicating that BioLargo is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Flexible Solutions International 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioLargo 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ZTEK or BLGO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zentek 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioLargo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation and earnings, ZTEK or BLGO?

BioLargo has higher revenue and earnings than Zentek. Zentek is trading at a lower price-to-earnings ratio than BioLargo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zentek $166.05K 405.37 -$7.07M -$0.07 N/A BioLargo $12.23M 3.01 -$3.50M -$0.04 N/A

Is ZTEK or BLGO more profitable?

BioLargo has a net margin of -11.45% compared to Zentek's net margin of -5,848.76%. BioLargo's return on equity of -39.90% beat Zentek's return on equity. Company Net Margins Return on Equity Return on Assets Zentek -5,848.76% -81.95% -57.78% BioLargo -11.45% -39.90% -22.06%

Does the media prefer ZTEK or BLGO?

In the previous week, Zentek had 1 more articles in the media than BioLargo. MarketBeat recorded 3 mentions for Zentek and 2 mentions for BioLargo. BioLargo's average media sentiment score of 0.46 beat Zentek's score of 0.36 indicating that BioLargo is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentek 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioLargo 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

BioLargo (BLGO) Competitors

$0.11 0.00 (-2.09%)

As of 07/24/2026 03:46 PM Eastern

Compare

BLGO vs. CBUS, AMTX, ARQ, FSI, and ZTEK

Should you buy BioLargo stock or one of its competitors? MarketBeat compares BioLargo with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioLargo include Cibus (CBUS), Aemetis (AMTX), ARQ (ARQ), Flexible Solutions International (FSI), and Zentek (ZTEK). These companies are all part of the "chemicals" industry.

How does BioLargo compare to Cibus?

Cibus (NASDAQ:CBUS) and BioLargo (NASDAQ:BLGO) are both small-cap chemicals companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

BioLargo has a net margin of -11.45% compared to Cibus' net margin of -2,366.33%. BioLargo's return on equity of -39.90% beat Cibus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cibus	-2,366.33%	-200.87%	-28.28%
BioLargo	-11.45%	-39.90%	-22.06%

Cibus has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market. Comparatively, BioLargo has a beta of -0.12, meaning that its stock price is 112% less volatile than the broader market.

In the previous week, Cibus had 4 more articles in the media than BioLargo. MarketBeat recorded 6 mentions for Cibus and 2 mentions for BioLargo. Cibus' average media sentiment score of 0.77 beat BioLargo's score of 0.46 indicating that Cibus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cibus	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioLargo	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioLargo has higher revenue and earnings than Cibus. BioLargo is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cibus	$3.64M	35.65	-$127.08M	-$1.97	N/A
BioLargo	$12.23M	3.01	-$3.50M	-$0.04	N/A

Cibus currently has a consensus target price of $9.00, indicating a potential upside of 429.41%. Given Cibus' stronger consensus rating and higher possible upside, equities research analysts plainly believe Cibus is more favorable than BioLargo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cibus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioLargo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

33.8% of Cibus shares are owned by institutional investors. Comparatively, 0.0% of BioLargo shares are owned by institutional investors. 31.2% of Cibus shares are owned by insiders. Comparatively, 19.3% of BioLargo shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Cibus beats BioLargo on 10 of the 16 factors compared between the two stocks.

How does BioLargo compare to Aemetis?

Aemetis (NASDAQ:AMTX) and BioLargo (NASDAQ:BLGO) are both small-cap chemicals companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

Aemetis presently has a consensus price target of $11.88, suggesting a potential upside of 604.75%. Given Aemetis' stronger consensus rating and higher possible upside, research analysts plainly believe Aemetis is more favorable than BioLargo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aemetis	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioLargo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

BioLargo has lower revenue, but higher earnings than Aemetis. BioLargo is trading at a lower price-to-earnings ratio than Aemetis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aemetis	$197.63M	0.60	-$77M	-$1.19	N/A
BioLargo	$12.23M	3.01	-$3.50M	-$0.04	N/A

Aemetis has a beta of 1.44, indicating that its stock price is 44% more volatile than the broader market. Comparatively, BioLargo has a beta of -0.12, indicating that its stock price is 112% less volatile than the broader market.

BioLargo has a net margin of -11.45% compared to Aemetis' net margin of -35.43%. Aemetis' return on equity of 0.00% beat BioLargo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aemetis	-35.43%	N/A	-33.44%
BioLargo	-11.45%	-39.90%	-22.06%

In the previous week, Aemetis had 1 more articles in the media than BioLargo. MarketBeat recorded 3 mentions for Aemetis and 2 mentions for BioLargo. Aemetis' average media sentiment score of 0.83 beat BioLargo's score of 0.46 indicating that Aemetis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aemetis	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioLargo	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

27.0% of Aemetis shares are held by institutional investors. Comparatively, 0.0% of BioLargo shares are held by institutional investors. 13.0% of Aemetis shares are held by company insiders. Comparatively, 19.3% of BioLargo shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Aemetis beats BioLargo on 10 of the 16 factors compared between the two stocks.

How does BioLargo compare to ARQ?

ARQ (NASDAQ:ARQ) and BioLargo (NASDAQ:BLGO) are both small-cap chemicals companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

ARQ has a beta of 2, indicating that its stock price is 100% more volatile than the broader market. Comparatively, BioLargo has a beta of -0.12, indicating that its stock price is 112% less volatile than the broader market.

18.5% of ARQ shares are held by institutional investors. Comparatively, 0.0% of BioLargo shares are held by institutional investors. 20.1% of ARQ shares are held by insiders. Comparatively, 19.3% of BioLargo shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

BioLargo has a net margin of -11.45% compared to ARQ's net margin of -43.93%. ARQ's return on equity of -2.67% beat BioLargo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARQ	-43.93%	-2.67%	-2.00%
BioLargo	-11.45%	-39.90%	-22.06%

In the previous week, ARQ had 1 more articles in the media than BioLargo. MarketBeat recorded 3 mentions for ARQ and 2 mentions for BioLargo. ARQ's average media sentiment score of 0.63 beat BioLargo's score of 0.46 indicating that ARQ is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARQ	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioLargo	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ARQ presently has a consensus price target of $5.00, suggesting a potential upside of 146.31%. Given ARQ's stronger consensus rating and higher probable upside, equities analysts plainly believe ARQ is more favorable than BioLargo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARQ	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioLargo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

BioLargo has lower revenue, but higher earnings than ARQ. BioLargo is trading at a lower price-to-earnings ratio than ARQ, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARQ	$122.14M	0.71	-$52.61M	-$1.29	N/A
BioLargo	$12.23M	3.01	-$3.50M	-$0.04	N/A

Summary

ARQ beats BioLargo on 12 of the 16 factors compared between the two stocks.

How does BioLargo compare to Flexible Solutions International?

Flexible Solutions International (NYSE:FSI) and BioLargo (NASDAQ:BLGO) are both small-cap chemicals companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Flexible Solutions International	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	3.00
BioLargo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Flexible Solutions International has higher revenue and earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than Flexible Solutions International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Flexible Solutions International	$39.34M	1.62	$2.78M	$0.06	83.50
BioLargo	$12.23M	3.01	-$3.50M	-$0.04	N/A

54.3% of Flexible Solutions International shares are held by institutional investors. Comparatively, 0.0% of BioLargo shares are held by institutional investors. 35.8% of Flexible Solutions International shares are held by insiders. Comparatively, 19.3% of BioLargo shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Flexible Solutions International had 2 more articles in the media than BioLargo. MarketBeat recorded 4 mentions for Flexible Solutions International and 2 mentions for BioLargo. BioLargo's average media sentiment score of 0.46 beat Flexible Solutions International's score of 0.40 indicating that BioLargo is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Flexible Solutions International	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioLargo	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Flexible Solutions International has a net margin of 10.80% compared to BioLargo's net margin of -11.45%. Flexible Solutions International's return on equity of 10.61% beat BioLargo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Flexible Solutions International	10.80%	10.61%	7.32%
BioLargo	-11.45%	-39.90%	-22.06%

Flexible Solutions International has a beta of 1.63, suggesting that its share price is 63% more volatile than the broader market. Comparatively, BioLargo has a beta of -0.12, suggesting that its share price is 112% less volatile than the broader market.

Summary

Flexible Solutions International beats BioLargo on 13 of the 15 factors compared between the two stocks.

How does BioLargo compare to Zentek?

Zentek (NASDAQ:ZTEK) and BioLargo (NASDAQ:BLGO) are both small-cap chemicals companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

BioLargo has higher revenue and earnings than Zentek. Zentek is trading at a lower price-to-earnings ratio than BioLargo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentek	$166.05K	405.37	-$7.07M	-$0.07	N/A
BioLargo	$12.23M	3.01	-$3.50M	-$0.04	N/A

Zentek has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market. Comparatively, BioLargo has a beta of -0.12, suggesting that its stock price is 112% less volatile than the broader market.

0.8% of Zentek shares are held by institutional investors. Comparatively, 0.0% of BioLargo shares are held by institutional investors. 19.3% of BioLargo shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Zentek had 1 more articles in the media than BioLargo. MarketBeat recorded 3 mentions for Zentek and 2 mentions for BioLargo. BioLargo's average media sentiment score of 0.46 beat Zentek's score of 0.36 indicating that BioLargo is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zentek	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioLargo	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioLargo has a net margin of -11.45% compared to Zentek's net margin of -5,848.76%. BioLargo's return on equity of -39.90% beat Zentek's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentek	-5,848.76%	-81.95%	-57.78%
BioLargo	-11.45%	-39.90%	-22.06%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentek	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioLargo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

BioLargo beats Zentek on 8 of the 14 factors compared between the two stocks.

Get BioLargo News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLGO vs. The Competition

Export

Metric	BioLargo	Chemicals & allied products Industry	Construction Sector	NASDAQ Exchange
Market Cap	$36.83M	$7.93B	$9.54B	$12.26B
Dividend Yield	N/A	1.09%	2.01%	9.79%
P/E Ratio	-11.26	N/A	18.73	23.64
Price / Sales	3.01	2.59	26.78	89.27
Price / Cash	N/A	270.17	16.44	59.64
Price / Book	11.26	7.07	5.42	6.07
Net Income	-$3.50M	$659.84M	$557.36M	$331.99M
7 Day Performance	4.16%	1.39%	-1.00%	-0.63%
1 Month Performance	5.04%	1.68%	-6.61%	-2.00%
1 Year Performance	-40.52%	-12.58%	2.85%	13.62%

BioLargo Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLGO BioLargo	N/A	$0.11 -2.1%	N/A	-38.5%	$36.83M	$12.23M	N/A	30	News Coverage
CBUS Cibus	1.9966 of 5 stars	$1.81 -13.0%	$9.00 +397.2%	+3.0%	$138.16M	$3.64M	N/A	48	News Coverage Analyst Upgrade
AMTX Aemetis	2.0723 of 5 stars	$1.56 -4.3%	$11.88 +661.2%	-48.5%	$109.78M	$197.63M	N/A	160	News Coverage
ARQ ARQ	4.0115 of 5 stars	$2.18 -0.9%	$5.00 +129.4%	-64.9%	$93.58M	$122.14M	N/A	140	News Coverage
FSI Flexible Solutions International	2.5666 of 5 stars	$6.17 -0.3%	N/A	-11.3%	$78.69M	$39.34M	18.71	40	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BLGO) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioLargo (BLGO) Competitors